AffaMed Therapeutics rakes in over $170m Series B
AffaMed Therapeutics, a global clinical-stage biopharmaceutical company, has raised over $170 million in Series B financing.
AffaMed Therapeutics, a global clinical-stage biopharmaceutical company, has raised over $170 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination